Scarica l'app Stockscreener
303.64
3.78%
11.06
Dopo l'orario di chiusura:
304.39
0.75
+0.25%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALNY Giù?
Forum
Previsione
Precedente Chiudi:
$292.58
Aprire:
$297.22
Volume 24 ore:
1.08M
Relative Volume:
0.99
Capitalizzazione di mercato:
$40.54B
Reddito:
$4.29B
Utile/perdita netta:
$577.22M
Rapporto P/E:
72.15
EPS:
4.2086
Flusso di cassa netto:
$641.34M
1 W Prestazione:
-0.47%
1M Prestazione:
+1.92%
6M Prestazione:
-34.64%
1 anno Prestazione:
-0.55%
Intervallo 1D:
$293.85
$310.53
Intervallo di 1 settimana:
$283.10
$310.53
Portata 52W:
$283.10
$495.55
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Nome
Alnylam Pharmaceuticals Inc
Settore
Industria
Telefono
(617) 551-8200
Indirizzo
675 WEST KENDALL STREET, CAMBRIDGE, MA
Compare ALNY vs VRTX, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
303.64 | 39.06B | 4.29B | 577.22M | 641.34M | 4.2086 |
VRTX
Vertex Pharmaceuticals Inc
|
441.74 | 108.72B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
628.73 | 64.89B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
842.27 | 50.57B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
155.69 | 33.16B | 742.00K | -1.37B | -1.07B | -7.0731 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-16 | Downgrade | Jefferies | Buy → Hold |
| 2026-01-28 | Ripresa | Barclays | Overweight |
| 2026-01-07 | Ripresa | Oppenheimer | Outperform |
| 2025-08-04 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-08-04 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | Ripresa | Raymond James | Outperform |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-03-31 | Iniziato | Redburn Atlantic | Buy |
| 2025-03-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-11-12 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-08-16 | Aggiornamento | Goldman | Neutral → Buy |
| 2024-02-16 | Downgrade | Goldman | Buy → Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2023-12-08 | Iniziato | Wells Fargo | Equal Weight |
| 2023-10-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-09-29 | Iniziato | Raymond James | Outperform |
| 2023-05-05 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | Iniziato | SMBC Nikko | Neutral |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Buy |
| 2022-09-09 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-27 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-06-07 | Iniziato | William Blair | Outperform |
| 2022-04-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | Iniziato | Citigroup | Buy |
| 2022-02-03 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-01-03 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | Aggiornamento | Goldman | Neutral → Buy |
| 2021-11-22 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-10-04 | Aggiornamento | UBS | Neutral → Buy |
| 2021-08-04 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-02-12 | Downgrade | Citigroup | Buy → Neutral |
| 2021-02-12 | Reiterato | H.C. Wainwright | Buy |
| 2021-01-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | Ripresa | Berenberg | Hold |
| 2020-09-08 | Iniziato | Citigroup | Buy |
| 2020-08-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-04-24 | Ripresa | Evercore ISI | Outperform |
| 2020-03-19 | Iniziato | Berenberg | Buy |
| 2019-12-19 | Reiterato | Chardan Capital Markets | Buy |
| 2019-11-20 | Iniziato | Oppenheimer | Outperform |
| 2019-11-13 | Iniziato | BofA/Merrill | Buy |
| 2019-05-23 | Ripresa | Goldman | Neutral |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-03-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2019-03-05 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | Iniziato | UBS | Neutral |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-08-13 | Reiterato | Stifel | Buy |
| 2018-08-07 | Aggiornamento | Stifel | Hold → Buy |
| 2018-05-04 | Reiterato | Stifel | Hold |
| 2018-03-28 | Iniziato | Evercore ISI | In-line |
Mostra tutto
Alnylam Pharmaceuticals Inc Borsa (ALNY) Ultime notizie
Alnylam Pharmaceuticals (ALNY) Partners with Inceptive Nucleics to Enhance Drug Discovery - GuruFocus
ALNY Reiterated by HC Wainwright & Co. -- Maintains Price Target at $510 - GuruFocus
Alnylam Eyes Faster Drug Discovery With AI Partnership Worth Up To $2 Billion - Benzinga
Alnylam, Inceptive ink AI deal potentially worth $2B - BioPharma Dive
Alnylam Bets on AI for Speedy RNAi Drug Discovery and Development - Yahoo Finance
Alnylam, Inceptive Sign AI-RNAi Drug Discovery Deal Worth Up To $2bn - Citeline News & Insights
ATTR treatment landscape heats up as clinical progress gathers pace - The Pharma Letter
Alnylam signs $2 billion AI pact with Inceptive - The Pharma Letter
AI Collaboration Puts Alnylam’s RNAi Pipeline Productivity In Focus - simplywall.st
Alnylam (ALNY) Partners with Inceptive Nucleics for $2B Innovati - GuruFocus
Alnylam (ALNY) Partners with Inceptive Nucleics for $2B Innovation Deal - GuruFocus
Alnylam Pharmaceuticals (ALNY) Partners with Inceptive Nucleics for AI-Driven RNAi Development - GuruFocus
Alnylam stock rises on $2B AI drug discovery partnership By Investing.com - Investing.com Nigeria
Alnylam, Inceptive form AI drug discovery collaboration - Investing.com
Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics - 01net
Alnylam, Inceptive sign up to $2 billion AI drug discovery deal - Reuters
Alnylam director Pyott sells $1.15m in stock - Investing.com
Alnylam (ALNY) director sells 3,830 shares after expiring option exercise - Stock Titan
Alnylam Pharmaceuticals (ALNY) director receives 4,393 stock options grant - Stock Titan
Benjamin Cravatt joins ALNYLAM PHARMACEUTICALS (ALNY) board and files Form 3 - Stock Titan
Alnylam Pharmaceuticals stock hits 52-week low at $283.58 By Investing.com - Investing.com India
Homozygous Familial Hypercholesterolemia Market Unlocking New Revenue Opportunities and Strategic Expansion by 2036 – DelveInsight | Arrowhead Pharma, Novartis, Alnylam Pharma, LIB Therapeutics - Barchart.com
Alnylam Pharmaceuticals stock hits 52-week low at $283.58 - Investing.com
Avoiding Lag: Real-Time Signals in (ALNY) Movement - Stock Traders Daily
[144] ALNYLAM PHARMACEUTICALS, INC. SEC Filing - Stock Titan
ALNY Stock Price, Quote & Chart | ALNYLAM PHARMACEUTICALS INC (NASDAQ:ALNY) - ChartMill
Are options traders betting on a big move in Alnylam stock? - MSN
Alnylam Pharmaceuticals (NASDAQ:ALNY) Shows Strong Alignment with the Little Book That Makes You Rich Growth Strategy - ChartMill
Alnylam Pharmaceuticals (ALNY) Stock Analysis: A Biotech Powerhouse with 47.63% Potential Upside - DirectorsTalk Interviews
Are Options Traders Betting on a Big Move in Alnylam Stock? - TradingView
ALNY News | ALNYLAM PHARMACEUTICALS INC (NASDAQ:ALNY) - ChartMill
How Investors May Respond To Alnylam Pharmaceuticals (ALNY) Adding Scientific Depth Amid RNAi Pipeline Scrutiny - simplywall.st
Hereditary Transthyretin Amyloidosis (hATTR) Market Trends, Innovation, and Future Growth Outlook to 2036 – DelveInsight |Alnylam Pharma, Ionis Pharma, Novo Nordisk, AstraZeneca, Pfizer, Intellia - Barchart
Alnylam Pharmaceuticals, Inc. 8-K SEC Filing Summary – Corporate Details and Exchange Listing (May 20, 2026) - Minichart
Alnylam (NASDAQ: ALNY) expands board and details 2026 shareholder meeting votes - Stock Titan
Ionis, Alnylam, BioMarin up as Citi starts at buy on catalyst and growth outlook - MSN
RBC Capital Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $445 - Moomoo
ALNY Technical Analysis | Trend, Signals & Chart Patterns | ALNYLAM PHARMACEUTICALS INC (NASDAQ:ALNY) - ChartMill
Citi Initiates Alnylam (ALNY) With Buy Rating - Insider Monkey
Alnylam Pharmaceuticals Q3 2025 Earnings Preview - MSN
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis: A 49.88% Potential Upside for Biotech Investors - DirectorsTalk Interviews
Assessing Alnylam Pharmaceuticals (ALNY) Valuation After Mixed Share Performance And Strong AMVUTTRA Uptake - simplywall.st
Director at Alnylam (NASDAQ: ALNY) granted RSUs and stock options - Stock Titan
Alnylam (NASDAQ: ALNY) awards RSUs and options to board director - Stock Titan
Director at Alnylam (NASDAQ: ALNY) receives RSUs and options - Stock Titan
Alnylam (ALNY) director gets new RSUs, options and reports trust holdings - Stock Titan
Director Peter Kellogg granted RSUs and stock options at Alnylam (NASDAQ: ALNY) - Stock Titan
ALNY (ALNY) director granted 671 RSUs and 1,441 options at $298.48 - Stock Titan
Alnylam (ALNY) director Olivier Brandicourt receives new RSU and option grants - Stock Titan
ALNY (ALNY) director Dennis Ausiello granted RSUs and stock options awards - Stock Titan
Alnylam (ALNY) director granted RSUs and stock options in new equity awards - Stock Titan
Alnylam Pharmaceuticals Inc Azioni (ALNY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.19%
0.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):